Exchange: OTC·Updated 03:40 PM EDT
PETV logo

PETV PetVivo Holdings Inc

$0.758
$0.0214
(2.75%)
Today
EarningsNov 12
Mkt Cap$29.58M
Vol6,599.00

About PETV

PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company, which engages in the business of licensing and commercializing medical devices and biomaterials for the treatment and management of afflictions and diseases in animals, initially for dogs and horses. Its lead product includes Spryng with OsteoCushion Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses. The company was founded by John Lai and John F. Dolan on March 31, 2009 and is headquartered in Edina, MN.
46

Neutral Sentiment

How do you feel about PETV?

INSDigitalMedia
$PETV they've just replaced the board and now we're waiting on some sales updates. Could be a good time to add more.
1
Elephanthunter7
$PETV Very Impressive ! Specifically, Mr. Handley was one of the founders and on the management team of Vessix Vascular, Inc. in Laguna Hills California from 2011 to 2012. As a result of his work at Vessix Vascular the company was acquired for $435M by Boston Scientific. Before his time at Vessix Vascular, Mr. Handley was Global Head of Regulatory at Acclarent (that was acquired by Johnson & Johnson) from 2010 – 2011 and assisted in the integration of the $785M acquisition of Acclarent and their five product lines and driving the global revenue growth of the Ethicon franchise for ENT products. Prior to working with Acclarent/J&J, Mr. Handley was the Global Vice President of Regulatory Affairs and Chief Compliance Officer at Spectranetics Corporation, a NASDAQ listed (SPNC)
Elephanthunter7
$PETV Michael Handley Joins PetVivo Holdings, Inc. Board of Directors MINNEAPOLIS, MN, US, Sept. 22, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) (the “Company”), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, today announced the appointment of Michael K. Handley to its Board of Directors, effective September 22, 2026.

Advertisement|Remove ads.